Urology News and Research

Latest Urology News and Research

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

If you are a parent who has conceived using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Two other education fund prizes will also be awarded.

2 Mar 2010

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

Watson Pharmaceuticals, Inc. today announced that it signed an agreement on February 26, 2010 to divest its equity ownership position of approximately 31% of ScinoPharm Taiwan Ltd. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as well as other customary closing conditions.

2 Mar 2010

Physicians urge Senators to repeal Medicare cuts

The U.S. Senate's failure to act before today's 21 percent Medicare physician payment cut has put seniors at grave risk of reduced access to health care and choice of physician.

1 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

1 Mar 2010

Kidney Cancer Canada: Survival, support, understanding, research and hope

Survival. Support. Understanding. Research. Hope. These are five words that mean a great deal to Kidney Cancer Canada as National Kidney Month kicks off this March.

27 Feb 2010

New Robotic Surgical Simulator created for robot-assisted surgery

A collaboration between the Center for Robotic Surgery at Roswell Park Cancer Institute and the University at Buffalo's School of Engineering and Applied Sciences has produced one of the world's first simulators that closely approximates the "touch and feel" of the da Vinci- robotic surgical system.

26 Feb 2010

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Ferring Pharmaceuticals and Gene Security Network announced that they have signed an agreement to conduct a clinical trial of GSN's advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™.

26 Feb 2010

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.

25 Feb 2010

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Watson Pharmaceuticals, Inc. today reported net revenue for the fourth quarter ended December 31, 2009 climbed 22 percent to $785.7 million, compared to $645.2 million in the fourth quarter 2008.

24 Feb 2010

Nation-wide study to assess risk of suicide among men

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa.

23 Feb 2010

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

23 Feb 2010

Rewarding health care organizations for large-scale improvement will help accelerate improvement in care and quality

Rewarding health care organizations for achieving large-scale, population-based improvement has significant potential to accelerate the spread of evidence-based interventions, improve quality, and control costs at a national level, according to a commentary in the February 17 issue of the Journal of the American Medical Association.

22 Feb 2010

Robot-assisted surgery advantageous over laparoscopic surgery for uretero-pelvic junction obstruction

A comparison of two types of minimally invasive surgery to repair kidney blockages that prevent urine from draining normally to the bladder found that robot-assisted surgery was faster and resulted in less blood loss and shorter hospital stays.

22 Feb 2010

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Of the 200,000 men newly diagnosed with prostate cancer each year in the United States, about one-third will undergo surgical treatment. Although open radical prostatectomy (ORP) is regarded as the standard treatment, laparoscopic radical prostatectomy (LRP) with or without robotic assistance is becoming more common.

22 Feb 2010

Urology News and Research

Latest Urology News and Research

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Allergan celebrates 20th anniversary of BOTOX in Canada

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

Physicians urge Senators to repeal Medicare cuts

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Kidney Cancer Canada: Survival, support, understanding, research and hope

New Robotic Surgical Simulator created for robot-assisted surgery

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Nation-wide study to assess risk of suicide among men

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Rewarding health care organizations for large-scale improvement will help accelerate improvement in care and quality

Robot-assisted surgery advantageous over laparoscopic surgery for uretero-pelvic junction obstruction

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in